London Health Sciences Centre

Running trials

• Not yet recruiting

  Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access

  NCT07858331· Phase 4· Kristin Clemens· Source

• Not yet recruiting

  Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)

  NCT07831122· Phase 1· Canadian Myeloma Research Group· Source

• Not yet recruiting

  A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression in Limited-Stage Small Cell Lung Cancer

  NCT07920549· Phase 2/3· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source

• Not yet recruiting

  The BASIC-S Feasibility Study for Vascular Risk Reduction

  NCT07755631· Andrew Appleton· Source

• Recruiting

  TRIal of PPF3 vs. PlaCEbo in the TReatment of Children and AdolescenTs With NeurOdeveloPmental DisorderS

  NCT07893964· Phase 2· Holland Bloorview Kids Rehabilitation Hospital· Source

• Not yet recruiting

  Trauma Therapy for Weight-Based Bullying in Children

  NCT07685990· Western University· Source

• Not yet recruiting

  MICRO-ultrasound Guided Prostate SBRT

  NCT07737457· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source

• Not yet recruiting

  Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1)

  NCT07680322· Phase 2· Aeovian Pharmaceuticals, Inc.· Source

• Enrolling by invitation

  Implementation of Acute Heart Failure Checklist

  NCT07727304· Ottawa Hospital Research Institute· Source

• Recruiting

  A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

  NCT07521007· Phase 2· Beijing Inno Medicine Co., Ltd.· Source

• Recruiting

  Focal Versus Whole Gland High Dose-Rate Brachytherapy (HDR-BT) Boost to External Beam Radiotherapy in Localized Prostate Cancer: A Phase 2 Randomized Trial

  NCT07300566· Joelle Helou· Source

• Not yet recruiting

  Staph Nasal Decolonization to Improve Function and Feeding

  NCT07524894· Phase 2· David Palma· Source

• Recruiting

  Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

  NCT07392892· Phase 2/3· Pfizer· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

  NCT07416604· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation

  NCT07192016· Phase 4· Western University, Canada· Source

• Recruiting

  Restrictive Fluid Management In Liver Transplantation (REFIL)

  NCT07695363· Centre hospitalier de l'Université de Montréal (CHUM)· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Janssen Research & Development, LLC· Source

• Not yet recruiting

  FMT in Triple Negative Breast Cancer Guided by ctDNA

  NCT07292142· Phase 1/2· Jewish General Hospital· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Pfizer· Source

• Not yet recruiting

  SMART-PD: Evaluating the Impact of Smartphone-Based Wearable Technology on Motor Symptoms and Quality of Life in People With Parkinson's Disease

  NCT07066163· Western University· Source

• Recruiting

  Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication

  NCT07272902· Nova Scotia Health Authority· Source

• Recruiting

  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  NCT07128199· Phase 3· Taiho Oncology, Inc.· Source

• Recruiting

  Oral Carnitine in Heart Failure Patients

  NCT07201714· Early phase 1· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.

  NCT07027436· Phase 3· Hamilton Health Sciences Corporation· Source

• Not yet recruiting

  Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy

  NCT07076914· Phase 2· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source

• Active, not recruiting

  Study of COYA 302 for the Treatment of ALS

  NCT07161999· Phase 2/3· Coya Therapeutics· Source

• Recruiting

  Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

  NCT06745908· Phase 3· ImmunityBio, Inc.· Source

• Recruiting

  Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

  NCT06942039· Early phase 1· C17 Council· Source

• Recruiting

  DIALysis With EXpanded Solute Removal

  NCT06660277· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source

• Recruiting

  A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

  NCT07100119· Phase 1· Eli Lilly and Company· Source

• Recruiting

  A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

  NCT07071519· Phase 3· AbbVie· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Exelixis· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  NCT06997497· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· Phase 3· Takeda· Source

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial

  NCT06337838· Phase 3· Hamilton Health Sciences Corporation· Source

• Recruiting

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  NCT06952504· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma

  NCT06850766· Ottawa Hospital Research Institute· Source

• Recruiting

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· Phase 3· Takeda· Source

• Recruiting

  A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  NCT06846671· Phase 3· BeOne Medicines· Source

• Recruiting

  AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

  NCT06665165· Phase 1· Amylyx Pharmaceuticals Inc.· Source

• Recruiting

  The Dragon PLC Trial (DRAGON-PLC)

  NCT06914648· Maastricht University· Source

• Not yet recruiting

  Genomic First Testing in Chronic Kidney Disease

  NCT06794567· Dervla Connaughton· Source

• Recruiting

  Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease

  NCT05986318· Phase 2· David Palma· Source

• Not yet recruiting

  Surgery and Reducing Ionizing Radiation of the Unknown Primary

  NCT06578871· Phase 2· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source

• Active, not recruiting

  A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

  NCT06593522· Phase 2· Amgen· Source

• Recruiting

  Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

  NCT06736574· Phase 3· Cytokinetics· Source

Showing 50 of 174.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease8 recruiting
• Lung cancer7 recruiting
• Crohn's disease6 recruiting
• Obesity5 recruiting
• Prostate cancer5 recruiting
• Heart failure4 recruiting
• Ulcerative colitis4 recruiting
• Atrial fibrillation3 recruiting
• Childhood cancers3 recruiting
• Colorectal cancer3 recruiting
• Epilepsy3 recruiting
• Head and neck cancer3 recruiting
• Liver and biliary tract cancer3 recruiting
• Migraine3 recruiting
• Multiple myeloma3 recruiting
• Osteoarthritis3 recruiting
• Stroke3 recruiting
• ALS (motor neurone disease)2 recruiting
• Alzheimer disease2 recruiting
• Cervical cancer2 recruiting
• Coronary artery disease2 recruiting
• Parkinson disease2 recruiting
• Sarcoidosis2 recruiting
• Aortic aneurysm1 recruiting
• Aortic stenosis1 recruiting
• Asthma1 recruiting
• Autism1 recruiting
• Bladder cancer1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• COPD1 recruiting
• Endometrial cancer1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Glioblastoma1 recruiting
• Haemophilia1 recruiting
• High blood pressure1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• IgA nephropathy1 recruiting
• Myelodysplastic syndromes1 recruiting
• Neuroblastoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Peripheral artery disease1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Takeda· Source

• Recruiting

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· Phase 3· Incyte Corporation· Source

• Completed

  Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR)

  NCT06203977· Phase 2· Hamilton Health Sciences Corporation· Source

• Completed

  MED-EL Remote Care Multi-Center Feasibility Study

  NCT05973669· Med-El Corporation· Source

• Completed

  Real-World Effectiveness of Mavacamten in Canada

  NCT06338202· Bristol-Myers Squibb· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  The Extended CTA for the Successful Screening of Cardioaortic Thrombus in Acute Ischemic Stroke and TIA (DAYLIGHT) Trial

  NCT05522244· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source

• Completed

  Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend

  NCT05118893· Anthony Tang· Source

• Completed

  Continuation of Patient Follow-up to 2 Years for the Pinnacle RSA and Pinnacle DM RSA Clinical Trials

  NCT05930067· Canadian Radiostereometric Analysis Network· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  TESTING -ON Post-Trial ObservatioNal Cohort Study

  NCT05434325· The George Institute· Source

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Completed

  ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

  NCT05081245· Phase 2· MapLight Therapeutics· Source

• Completed

  Clinic to Community© Program for Adults With Epilepsy Admitted to Emergency Departments

  NCT04248920· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source

• Terminated

  THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)

  NCT05033314· Phase 3· University Health Network, Toronto· Source

• Completed

  Virtual Reality for Port-a-Cath Access

  NCT04931745· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source

• Completed

  Radioligand fOr locAl raDiorecurrent proStaTe cancER

  NCT05230251· Phase 1/2· Glenn Bauman· Source

• Completed

  Same Day Discharge for Wedge Resection

  NCT05067738· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source

• Completed

  A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)

  NCT04779307· Phase 3· Takeda· Source

• Completed

  RSA - ACTIS Hip Stem

  NCT04879732· Canadian Radiostereometric Analysis Network· Source

• Terminated

  A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis

  NCT04948645· Phase 1· AbbVie· Source

• Completed

  A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)

  NCT04299464· Phase 2· Hoffmann-La Roche· Source

• Terminated

  Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

  NCT04632940· Phase 3· Kyntra Bio· Source

• Completed

  A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

  NCT04766723· Phase 2· Merz Pharmaceuticals GmbH· Source

• Completed

  Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy

  NCT04053842· Phase 2· Glenn Bauman· Source

• Completed

  Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer.

  NCT04644822· Phase 3· Centre for Probe Development and Commercialization· Source

• Completed

  Inpatient vs Outpatient Total Knee Replacement

  NCT04228731· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source

• Completed

  A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

  NCT04266795· Phase 2· Takeda· Source

• Completed

  HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers

  NCT04670016· University of Calgary· Source

• Completed

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· Phase 3· Amgen· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT04182204· Phase 3· Hoffmann-La Roche· Source

• Completed

  Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

  NCT04029480· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

  NCT03832998· Phase 3· Amgen· Source

• Completed

  Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

  NCT03904693· Phase 3· Actelion· Source

• Completed

  Molecular Diagnosis of Idiopathic Interstitial Pneumonias: a Prospective Study

  NCT03836417· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source

• Completed

  I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

  NCT03939689· Phase 2· Progenics Pharmaceuticals, Inc.· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Boehringer Ingelheim· Source

• Completed

  Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

  NCT03713593· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  PRO-ACTIVE: Prophylactic Swallow Intervention for Patients Receiving Radiotherapy for Head and Neck Cancer

  NCT03455608· University Health Network, Toronto· Source

• Completed

  PSMA-PET Registry for Recurrent Prostate Cancer

  NCT03718260· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source

• Completed

  RSA of the ATTUNE Knee System: RCT Comparing Traditional Vs Enhanced-Fixation Device Designs

  NCT03554720· Canadian Radiostereometric Analysis Network· Source

• Completed

  Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

  NCT03517449· Phase 3· Eisai Inc.· Source

• Completed

  Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

  NCT03511664· Phase 3· Endocyte· Source

• Terminated

  A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  NCT03452137· Phase 3· Hoffmann-La Roche· Source

• Completed

  Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

  NCT03048825· Phase 3· Population Health Research Institute· Source

• Completed

  Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

  NCT03555422· Phase 3· Karyopharm Therapeutics Inc· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

  NCT03201965· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

  NCT03173560· Phase 2· Eisai Inc.· Source

• Completed

  COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors

  NCT03206021· Phase 1· The Hospital for Sick Children· Source

Showing 50 of 65.